Option chain shows key data for Matinas BioPharma Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Matinas BioPharma Hldgs.

Matinas BioPharma Hldgs (AMEX:MTNB) Stock, Option Chain

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

xr:d:DAFfORZ4lNo:2,j:2185570849,t:23040509

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

BAER

BNOX

BTCT

CERO

DXYZ

GRAB

LAZR

LGMK

LIFW

Eaton Vance Massachusetts Municipal Income Trust

NGNE

OGEN

TAOP

Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Uber stock

Earnings

Equities

Eurozone

Commodities

Intraday Update

ATEC

CMPS

LMND

ROOT

UBER

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

Atlassian is providing its financial targets as follows:
Third Quarter Fiscal Year 2025:
<ul>
<li>Cloud revenue growth year-over-year is expected to be approximately 23.5%.</li>
<li>Data Center revenue growth year-over-year is expected to be approximately 7.0%.</li>
<li>Marketplace and other revenue growth year-over-year is expected to be approximately flat.</li>
<li>Gross margin is expected to be approximately 82.0% on a GAAP basis and approximately 84.5% on a non-GAAP basis.</li>
<li>Operating margin is expected to be approximately (3.0%) on a GAAP basis and approximately 23.5% on a non-GAAP basis.</li>
</ul>

Guidance

TEAM

Atlassian Expects Q3 Total Revenue Of $1.345B - $1.353B (Est $1.313B)

KITT

LDOS

Leidos And Nauticus Robotics Enter Alliance To Advance Subsea Autonomy Solutions

GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) sees Q4 sales of $5.400 million-6.200 million.

GSIT

GSI Technology Sees Q4 Sales $5.400M-6.200M

WIIM

ENVB

Enveric Biosciences shares are trading higher after the company announced a notice of allowance for its lead drug candidate EB-003 from the U.S. Patent and Trademark Office.

Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.57 by 19.11 percent. This is a 42.75 percent increase over earnings of $1.31 per share from the same period last year. The company reported quarterly sales of $2.25 billion which missed the analyst consensus estimate of $2.27 billion by 1.24 percent. This is a 1.72 percent increase over sales of $2.21 billion the same period last year.

Earnings Beats

Earnings Misses

Eastman Chemical Q4 Adj $1.87 Beats $1.57 Estimate, Sales $2.25B Miss $2.27B Estimate

Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Olin beat estimated earnings by 325.0%, reporting an EPS of $0.09 versus an estimate of $-0.04.
Revenue was up $56.40 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company missed on EPS by $0.25, resulting in a 8.0% drop change in the share price the following day.
Here's a look at Olin's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>0.70</td>
<td>0.38</td>
<td>0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>0.62</td>
<td>0.40</td>
<td>0.43</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.57B</td>
<td>1.71B</td>
<td>1.65B</td>
<td>1.52B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.59B</td>
<td>1.64B</td>
<td>1.64B</td>
<td>1.61B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Olin <a href="https://www.benzinga.com/quote/OLN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Olin Earnings Analysis: Q4 Recap

Hewlett Packard Enterprise Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) shares are trading lower Thursday after the U.S. Department of Justice (DOJ) filed an antitrust lawsuit to block its proposed $14 billion a<a href="https://www.benzinga.com/pressreleases/25/01/b43347867/hewlett-packard-enterprise-and-juniper-networks-strongly-oppose-department-of-justices-decision-to">cquisition of Juniper Networks. </a>
What To Know: <a href="https://www.bloomberg.com/news/articles/2025-01-30/doj-sues-to-stop-hpe-s-14-billion-deal-to-buy-juniper-networks?sref=TBDibEcD">According to Bloomberg</a>, the DOJ argues the deal would significantly reduce competition in the enterprise wireless networking market by consolidating three major players — HPE, Juniper and Cisco Systems — down to two, with Cisco and a merged HPE-Juniper entity controlling approximately 70% of the market.
Regulators claim this level of concentration would limit customer choice, potentially leading to higher prices and slower innovation, particularly for large enterprises, universities and hospitals that rely on advanced networking infrastructure.
The lawsuit places both companies in a prolonged legal battle that could take months to resolve. HPE and Juniper have both pushed back against the DOJ's claims, arguing that the merger would actually enhance competition by strengthening their ability to challenge Cisco's dominance. They maintain that the deal would create a more viable alternative for customers and drive innovation in networking technology rather than hinder it.
The DOJ&#8217;s action signals an aggressive stance on corporate mergers, making this the first major antitrust challenge of President Donald Trump's current administration. The case is expected to play out over the coming months, with a final decision anticipated by Oct. 2025. If the court sides with regulators, HPE and Juniper may have to restructure the deal or abandon it entirely, while a successful defense could set a precedent for future consolidation in the tech sector.
HPE Price Action: Hewlett Packard shares closed Thursday down 2.12% at $21.19, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30145936/Screenshot-2025-01-30-at-14.59.09-1024x537.png" alt="" class="wp-image-758904" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30145936/Screenshot-2025-01-30-at-14.59.09-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30145936/Screenshot-2025-01-30-at-14.59.09-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30145936/Screenshot-2025-01-30-at-14.59.09-768x403.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30145936/Screenshot-2025-01-30-at-14.59.09.png 1188w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43311376/alibaba-ups-ai-game-says-its-qwen2-5-max-beats-deepseek-and-openai-in-performance">Alibaba Ups AI Game, Says Its Qwen2.5 Max Beats DeepSeek and OpenAI In Performance</a></li>
</ul>
Photo: Shutterstock.

Government

Legal

Tech

Hewlett Packard Enterprise Shares Fall As US Department Of Justice Sues To Block Juniper Acquisition

The earnings results for First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
First Business Finl Servs beat estimated earnings by 13.0%, reporting an EPS of $1.43 versus an estimate of $1.26.
Revenue was up $4.52 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.05, resulting in a 4.0% drop change in the share price the following day.
Here's a look at First Business Finl Servs's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.19</td>
<td>1.09</td>
<td>1.12</td>
<td>1.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.24</td>
<td>1.23</td>
<td>1.04</td>
<td>1.15</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>38.77M</td>
<td>37.25M</td>
<td>37.73M</td>
<td>37.47M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>38.07M</td>
<td>37.97M</td>
<td>36.28M</td>
<td>36.63M</td>
</tr>
</tbody>
</table>

To track all earnings releases for First Business Finl Servs <a href="https://www.benzinga.com/quote/FBIZ/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBIZ

Earnings Summary: First Business Finl Servs Q4

Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) announced its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.
Revenue was up $11.41 million from the same period last year.
<h3>Earnings History Overview</h3>
In the previous quarter, the company beat on EPS by $0.01, resulting in a 4.0% increase change in the share price the following day.
Here's a look at Standex International's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Standex International Q2

<a href="https://www.globenewswire.com/Tracker?data=bSnQYMuWkpBonwCKVG9eEy6g_qar2dx-bj3fyTX7Yg-mvavtiukmxImdYsIONHkRXBZvMTAQWPWSq7pEHb6weIkPKhLCulRwn-4Iyz8KUan-w2sGw7kw5BDvQTzbAXJ9DAP6a2TMxpSrugw9Flz0d1jvRmQvTFmVY5heWhwNrdChsApMjp4xu_VxYpKCEY0kUJpUwTA69auo6kQNJ_2J5rV1UWOc1-_FYA_Lx4X-icsJc1eo1XjpVEQzSKO8Lqi8hEPSKjBCquT1Csfd8OF5Z-w2Yt8xGjb8MQfGxudKJPr7eah2WvFwIa_yB4-q3LUsdfMvpdDb19VvPLoLfFBpg9kCPmsMAg3oSqKqWmE5F0BGQC640klahUcWMhAVtEuIoi6jttf00wv5AWZr8425cmwVgvSzA6S2vkpqJKSG_1u92pujjQXtieRtyTrEIO2l3bqZ4ciOT0DeCyJdCABvDxsIRUe1Vtgp-kBkkuyFmObK2DWgtQNTxmH-LQmYnonO4dt8vGJ137UNmk5EwOkOTOM-ddVlYRVKZyWo7aY5J9my6Uab-o5GGYlG3p9MIxfQyP_cTNz0HsdrVnExjAYGJRQXs-O6Y1YAFfHxB_TkCL8PlZTn97P4cZT0rPTs86nx">The Real Good Food Company, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) ("Real Good Foods" or the "Company "), a leading health and wellness frozen and refrigerated foods company, is announcing its intention to voluntarily delist its common stock from the Nasdaq Stock Market, LLC ("Nasdaq") and subsequently deregister with the Securities and Exchange Commission ("SEC"), following the decision of the Company's Board of Directors on January 27, 2025.
The decision to voluntarily delist and deregister from the SEC was made after careful consideration by the Board of Directors of various factors, including Nasdaq's announcement that it had suspended trading in the Company's stock and would eventually delist the Company, along with the significant financial and administrative requirements that come with being a public company.

RGFC

The Real Good Food Company Announces Intent To Voluntarily Delist From Nasdaq And Deregister With The SEC

The earnings results for Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:11 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Weyerhaeuser beat estimated earnings by 56.99999999999999%, reporting an EPS of $0.11 versus an estimate of $0.07.
Revenue was down $66.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.04, leading to a 1.0% drop share price change the next day.
Here's a look at Weyerhaeuser's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.01</td>
<td>0.21</td>
<td>0.15</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>0.21</td>
<td>0.16</td>
<td>0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.68B</td>
<td>1.95B</td>
<td>1.85B</td>
<td>1.86B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.68B</td>
<td>1.94B</td>
<td>1.80B</td>
<td>1.77B</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Weyerhaeuser <a href="https://www.benzinga.com/quote/WY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Weyerhaeuser: Q4 Earnings Insights

CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) has outperformed the market over the past 15 years by 1.47% on an annualized basis producing an average annual return of 13.73%. Currently, CSX has a market capitalization of $63.37 billion. 
Buying $100 In CSX: If an investor had bought $100 of CSX stock 15 years ago, it would be worth $698.65 today based on a price of $32.86 for CSX at the time of writing.
<h3>CSX's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738271712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

The earnings results for Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) for Q3 were made public on Thursday, January 30, 2025 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Cavco Indus beat estimated earnings by 41.0%, reporting an EPS of $6.9 versus an estimate of $4.89.
Revenue was up $75.27 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.52 in the previous quarter, leading to a 9.0% increase share price change the next day.
Here's a look at Cavco Indus's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>4.76</td>
<td>4.70</td>
<td>4.51</td>
<td>4.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.28</td>
<td>4.11</td>
<td>4.03</td>
<td>4.27</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>479.79M</td>
<td>462.32M</td>
<td>470.11M</td>
<td>425.88M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>507.46M</td>
<td>477.60M</td>
<td>420.12M</td>
<td>446.77M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Cavco Indus <a href="https://www.benzinga.com/quote/CVCO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVCO

Recap: Cavco Indus Q3 Earnings

GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) reported quarterly losses of $(0.16) per share. This is a 38.46 percent increase over losses of $(0.26) per share from the same period last year. The company reported $5.41 million in sales this quarter. This is a 1.81 percent increase over sales of $5.32 million the same period last year.

GSI Technology Q3 EPS $(0.16) Up From $(0.26) YoY, Sales $5.41M Up From $5.32M YoY

VIAV

Viavi Solutions shares are trading higher after the company reported better-than-expected Q2 financial results.

Gen Sees Q4 2025 Revenue $990M-$1.005B Vs $995.19M Estimate

Gen Digital shares are trading lower. The company reported Q3 financial results.

DECK

Deckers Outdoor shares are trading lower. The company reported Q3 financial results.

The following details guidance for the third quarter of fiscal 2025 ending in March:
<ul>
<li>GAAP gross margin is expected to be in a range of 60.6% +/- 1.0%</li>
<li>Non-GAAP gross margin is expected to be in a range of 62.0% +/- 1.0%</li>
<li>GAAP diluted EPS is expected to be in a range of $7.77 +/- $0.60</li>
</ul>

KLAC

KLA Expects Q3 Total Revenues Of $3.0B +/- $150M (Est $2.887B); Adj EPS Of $8.05 +/- $0.60 (Est $5.26)

PCB Bancorp (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>), the holding company of PCB Bank, announced that on January 29, 2025, its Board of Directors declared a quarterly cash dividend of $0.20 per common share. The dividend will be paid on or about February 21, 2025, to shareholders of record as of the close of business on February 14, 2025.

Dividends

PCB Bancorp Declares Increased Quarterly Cash Dividend From $0.18 To $0.20 Per Share

Press Releases

General

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Matinas BioPharma Receives NYSE Noncompliance Notice

111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.

BTIG

HC Wainwright & Co.

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga